scholarly journals Should All Pharmacists Entering a Patient Care Setting Have Completed (at Least) a Canadian Hospital Pharmacy Residency Board–Accredited Residency?

2010 ◽  
Vol 63 (2) ◽  
Author(s):  
Edward C Dillon (Pro) ◽  
David Hill (Con)
1972 ◽  
Vol 6 (11) ◽  
pp. 374-379
Author(s):  
Margaret C. Gebhardt ◽  
Stephen M. Caiola ◽  
Fred M. Eckel

The ostomate is often a forgotten patient with regards to proper psychological and emotional preparation for his surgery and proper continuing care of his ostomy. The pharmacist can play an important role in aiding the ostomy patient, especially in providing him adequate appliances and ostomy-care information. The development and implementation of the ostomy program of the N. C. Memorial Hospital Pharmacy is presented in detail. A brief explanation of why ostomy surgery is necessary, of the various types of ostomies and of the various appliances utilized is also presented. The following services of the program are described: Use of a patient profile card in order to have on record the patient's specific appliance and replacement parts; Fitting the new ostomate with the proper appliance and instructing him on its proper use; Interviewing patient on return clinic visits to determine if the patient is having ostomy-related problems or needs any replacement parts for his appliance; Providing patient's appliance needs through the mail or through communication with the patient's local community or hospital pharmacist, and Conducting a presurgical consultation with the future ostomate to briefly explain appliances and how their use will affect his life, plus answer questions which may be making him apprehensive.


2002 ◽  
Vol 14 (4) ◽  
pp. 359-367 ◽  
Author(s):  
Maureen Connor ◽  
Patricia Reid Ponte ◽  
James Conway
Keyword(s):  

2009 ◽  
Vol 44 (10) ◽  
pp. 868-869
Author(s):  
Joyce A. Generali ◽  
Dennis J. Cada

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. A summary of the most relevant data is provided, including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to hospital [email protected] .


2002 ◽  
Vol 37 (8) ◽  
pp. 871-876
Author(s):  
Brent I. Fox ◽  
Bill G. Felkey

An upcoming issue will feature readers' experiences with PDAs in the health care setting. Please e-mail any stories you would like to share with other Hospital Pharmacy readers to either of the authors at [email protected] or [email protected] . You may also send your contributions, questions, or comments to the authors (who share the same mailing address) at The Auburn University Harrison School of Pharmacy, Pharmacy Care Systems,128 Miller Hall, Auburn, AL 36849.


2005 ◽  
Vol 40 (2) ◽  
pp. 144-183
Author(s):  
Joyce Generali ◽  
Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected] .


2019 ◽  
Vol 15 (11) ◽  
pp. 1994-2001
Author(s):  
Margaret E. Smith ◽  
Aaron J. Bonham ◽  
Oliver A. Varban ◽  
Jonathan F. Finks ◽  
Arthur M. Carlin ◽  
...  

2020 ◽  
Vol 38 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Rebecca M. Crimmins ◽  
Lydia Elliott ◽  
Darren T. Absher

Context: Heart failure (HF) is a complex, life-limiting disease that is prevalent and burdensome. All major cardiology societies and international clinical practice guidelines recommend the integration of palliative care (PC) interventions alongside usual HF management. Objectives: The purpose of this review of the literature was to evaluate the various barriers to the early initiation of PC for HF patients in the primary care setting. Methods: An integrative literature review was conducted in order to assess and incorporate the diverse sources of literature available. An EBSCO search identified relevant articles in the following databases: Medline complete, Academic Search Premier, CINAHL, PsycINFO, Cochrane Library, and SocINDEX. The search was limited to full text, peer reviewed, English only, and published between 2010 and 2019. Results: Barriers to the integration of PC for HF patients include poor communication between provider/patient and interdisciplinary providers, the misperception and miseducation of what PC is and how it can be incorporated into patient care, the unpredictable disease trajectory of HF, and the limited time allowed for patient care in the primary care setting. Conclusion: The results of this review highlight a lack of communication, time, and knowledge as barriers to delivering PC. Primary care providers caring for patients with HF need to establish an Annual Heart Failure Review to meticulously evaluate symptoms and allow the time for communication involving prognosis, utilize a PC referral screening tool such as the Needs Assessment Tool: Progressive Disease-Heart Failure, and thoroughly understand the benefits and appropriate integration of PC.


2003 ◽  
Vol 38 (1) ◽  
pp. 25-26
Author(s):  
Joyce Generali ◽  
Dennis J. Cada

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to [email protected] .


Sign in / Sign up

Export Citation Format

Share Document